Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 6/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19401444 | 0.94 | CYP2C8 (0.65) | CYP2C8KCNH2CYP3A4NR1I2TP53 | |
| SCHEMBL19401415 | 0.94 | CYP2C8 (0.65) | CYP2C8KCNH2CYP3A4NR1I2TP53 | |
| SCHEMBL2140602 | 0.93 | CYP2C8 (0.75) | CYP2C8KCNH2CYP3A4NR1I2TP53 | |
| SCHEMBL15285827 | 0.92 | CYP2C8 (0.67) | CYP2C8KCNH2CYP3A4NR1I2TP53 | |
| SCHEMBL9900023 | 0.92 | CYP2C8 (0.67) | CYP2C8KCNH2CYP3A4NR1I2 | |
| SCHEMBL22407278 | 0.91 | CYP2C8 (0.66) | CYP2C8KCNH2CYP3A4NR1I2TP53 | |
| SCHEMBL19401373 | 0.91 | CYP2C8 (0.66) | CYP2C8KCNH2CYP3A4NR1I2TP53 | |
| SCHEMBL19401313 | 0.91 | CYP2C8 (0.68) | CYP2C8KCNH2CYP3A4NR1I2 | |
| SCHEMBL19385726 | 0.90 | CYP2C8 (0.65) | CYP2C8KCNH2CYP3A4NR1I2TP53 | |
| SCHEMBL15298815 | 0.90 | CYP2C8 (0.65) | CYP2C8KCNH2CYP3A4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200291002-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291002-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2017165233-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017165233-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291002-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HAVCR2, UGT2B7, GOT1 | CYP2C8 57/4885KCNH2 3469/4885CYP3A4 94/4885 |
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | HAVCR2, UGT2B7, GOT1 | CYP2C8 57/4885KCNH2 3469/4885CYP3A4 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.